A 31‐Year‐Old Man With A Fungal Infection, Elevated Alkaline Phosphatase Level, and Polyarthritis

2020 ◽  
Vol 72 (5) ◽  
pp. 601-606 ◽  
Author(s):  
Talha Khawar ◽  
Carsten R. Hamann ◽  
Arezoo Haghshenas ◽  
Allie Blackburn ◽  
Karina D. Torralba
Keyword(s):  
Alkaline Phosphatase ◽  
Fungal Infection ◽  
Alkaline Phosphatase Level ◽  
Elevated Alkaline Phosphatase

Case 14.26

2014 ◽  
pp. 723-724
Author(s):  
Christine U. Lee ◽  
James F. Glockner
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Scintigraphy ◽  
Prostate Carcinoma ◽  
Alkaline Phosphatase Level ◽  
Elevated Alkaline Phosphatase ◽  
Pelvic Mri ◽  
Axial Diffusion ◽  
Diffusion Weighted Images ◽  
Vertebral Bodies ◽  
Ct Contrast

64-year-old man with recently diagnosed prostate carcinoma and elevated alkaline phosphatase level; abdominal pelvic MRI was requested to screen for metastases in this patient with a severe allergy to iodinated CT contrast Axial diffusion-weighted images (b=800 s/mm2) (Figure 14.26.1) reveal multiple small hyperintense lesions involving lower thoracic and lumbar vertebral bodies, bilateral ribs, and the left iliac bone. Anterior and posterior views from bone scintigraphy (...

scholarly journals Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2304
Author(s):  
Joeri A. J. Douma ◽  
Laurien M. Buffart ◽  
Ramy Sedhom ◽  
Mariette Labots ◽  
Willemien C. Menke-van der Houven van Oordt ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Phase I ◽  
Alkaline Phosphatase Level ◽  
Phase I Trials ◽  
Opioid Use ◽  
Performance Score ◽  
Eligibility Criteria ◽  
Elevated Alkaline Phosphatase ◽  
Early Trial ◽  
Trial Discontinuation

Despite stringent eligibility criteria for trial participation, early discontinuation often occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we investigated predictors for early trial discontinuation. Data from 415 patients with solid tumors who participated in 66 trials were pooled for the current analysis. Early trial discontinuation was defined as (i) trial discontinuation within 28 days after start of treatment or (ii) discontinuation before administration of the first dosage in eligible patients. Multilevel logistic regression analyses were conducted to identify predictors for early trial discontinuation. Eighty-two participants (20%) demonstrated early trial discontinuation. Baseline sodium level below the lower limit of normal (OR = 2.95, 95%CI = 1.27–6.84), elevated alkaline phosphatase level >2.5 times the upper limit of normal (OR = 2.72, 95%CI = 1.49–4.99), performance score ≥ 1 (OR = 2.07, 95%CI = 1.03–4.19) and opioid use (OR = 1.82, 95%CI = 1.07–3.08) were independent predictors for early trial discontinuation. Almost 50% of the patients with hyponatremia and all four patients in whom all four predictors were present together discontinued the trial early. Hyponatremia, elevated alkaline phosphatase level, performance score ≥1 and opioid use were identified as significant predictors for early trial discontinuation. Hyponatremia was the strongest predictor and deserves consideration for inclusion in eligibility criteria for future trials.

SUBACUTE THYROIDITIS WITH ELEVATED SERUM ALKALINE PHOSPHATASE LEVEL

1960 ◽  
Vol XXXIV (II) ◽  
pp. 256-260
Author(s):  
Jörgen Herman Vogt
Keyword(s):  
Alkaline Phosphatase ◽  
Alkaline Phosphatase Level ◽  
Serum Alkaline Phosphatase ◽  
Thyroid Tissue ◽  
Elevated Serum ◽  
Subacute Thyroiditis ◽  
Serum Alkaline Phosphatase Level ◽  
Transient Rise

ABSTRACT A case of subacute thyroiditis is recorded, in which a transient rise in serum alkaline phosphatase values leads to the hypothesis of a transient parathyroid hyper-activity induced by the inflammation of the thyroid tissue in which the parathyroid may be embedded.

A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma.

1983 ◽  
Vol 1 (11) ◽  
pp. 720-726 ◽  
Author(s):  
C J Lahr ◽  
S J Soong ◽  
G Cloud ◽  
J W Smith ◽  
M M Urist ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Colorectal Carcinoma ◽  
Survival Rates ◽  
Elevated Serum ◽  
Hepatic Metastases ◽  
Lactic Dehydrogenase ◽  
Serum Bilirubin Level ◽  
Elevated Alkaline Phosphatase ◽  
Multifactorial Analysis ◽  
Primary Colorectal Tumor

A multifactorial analysis was used to identify the dominant prognostic variables predicting survival rates of 175 patients with hepatic metastases from colorectal carcinoma. Seven of 22 parameters examined simultaneously were found to independently influence the median survival rate in these patients: (1) elevated alkaline phosphatase (p = 0.0004), (2) elevated serum bilirubin level (p = 0.0005), (3) location of hepatic metastases (unilateral or bilateral, p = 0.0022), (4) number of metastatic nodes involved (0, 1-5, greater than 5; p = 0.0148), (5) depressed serum albumin (p = 0.0217), (6) whether or not the primary colorectal tumor was resected (p = 0.0013), and (7) chemotherapy (given or withheld, p = 0.0439). The prothrombin time, serum lactic dehydrogenase, and the number of hepatic metastases also correlated with survival, but they did not independently predict survival rates after other more dominant factors were accounted for. A mathematical equation for predicting an individual patient's clinical course once they developed hepatic metastases was derived from this statistical analysis. In addition, a simple and clinically useful guide for predicting outcome was developed that integrated the two most important risk factors, alkaline phosphatase and bilirubin.

Sign in / Sign up

Export Citation Format

Share Document